Intellia's CRISPR-engineered cell therapy secures FDA orphan drug status after AML trial launch

Intellia Therapeutics' CRISPR-powered T cell therapy, which uses the gene editing method to reprogram a sample of the patient's immune cells, has received an orphan drug designation from the FDA just eight days after the biotech disclosed that its first patient had been dosed with the treatment.